Do you want to read an article? Please log in or register.
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
Leukemia
Related content
Leukemia
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia
J Clin Oncol.
Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, Loren A, Svoboda J, Stadtmauer E, Landsburg DJ, Mato A, Levine BL, Lacey SF, Melenhorst JJ, Veloso E, Gaymon A, Pequignot E, Shan X, Hwang WT, June CH, Porter DL
doi: 10.1200/JCO.19.03237.
RECOMMENDED
Leukemia
Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis
★ 2
Recommended by
Alexander Meisel, Faculty Member
Lancet Haematol.
Anagnostou T, Riaz IB, Hashmi SK, Murad MH, Kenderian SS
doi: 10.1016/S2352-3026(20)30277-5.
Lymphoma
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
N Engl J Med.
Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH
doi: 10.1056/NEJMoa1708566.
RECOMMENDED
Leukemia
Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure
Blood.
Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH, Yeung CC, Sheih A, Pender BS, Hawkins RM, Vakil A, Phi TD, Steinmetz RN, Shadman M, Riddell SR, Maloney DG, Turtle CJ
doi: 10.1182/blood.2019002936.
Leukemia
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
J Clin Oncol.
Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, Ombrello A, Steinberg SM, Martin S, Delbrook C, Hoffman L, Little L, Ponduri A, Qin H, Qureshi H, Dulau-Florea A, Salem D, Wang HW, Yuan C, Stetler-Stevenson M, Panch S, Tran M, Mackall CL, Stroncek DF, Fry TJ
doi: 10.1200/JCO.19.03279.
Lymphoma
The CAR T Cell Story
healthbook TIMES Oncology Hematology
Russkamp N., Zenz T.
doi: 10.36000/hbT.OH.2019.01.001
Lymphoma
Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without co-targeting CD19
Clin Cancer Res.
Ormhøj M, Scarfò I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, Castano AP, Larson RC, Riley LS, Schmidts A, Choi BD, Andersen RS, Cédile O, Nyvold CG, Haaber J, Gjerstorff MF, Ditzel HJ, Weinstock DM, Barington T, Frigault MJ, Maus MV
doi: 10.1158/1078-0432.CCR-19-1337.
Leukemia
Interventions and Outcomes of Adult Patients with B-ALL Progressing After CD19 Chimeric Antigen Receptor T Cell Therapy
Blood
Wudhikarn K, Flynn JR, Rivière I, Gonen M, Wang X, Senechal B, Curran KJ, Roshal M, Maslak PG, Geyer MB, Halton EF, Diamonte C, Davila ML, Sadelain M, Brentjens RJ, Park J
doi: 10.1182/blood.2020009515
Leukemia
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
J Clin Oncol.
Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL
doi: 10.1200/JCO.19.01892.